Myriad Genetics Q4 revenue $177.8M (+11% YoY); GAAP EPS $(0.52), adjusted EPS $(0.12)

MYRIAD GENETICS INC

2022-FY EPS reported -$1.39 revenue$678,400,000

Q4 testing volumes up 26% YoY; hereditary cancer +16%, GeneSight +23%.
Full-year 2022 GeneSight revenue grew 36% to $127.6M.
FY2023 guidance: revenue $720-750M, adjusted EPS $(0.40)-$(0.20).
Q1 2023 guidance: revenue $170-172M, adjusted EPS $(0.20)-$(0.18).
Ended Q4 with $169.7M cash, no debt; cash used in ops $7.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MYRIAD GENETICS INC reported fourth quarter ended December 31, 2022 results: revenue $177.8 million, EPS $(0.52). Guidance initiated.

Period: fourth quarter ended December 31, 2022
Revenue: $177.8 million
EPS: $(0.52)
Guidance: initiated
Result: reported results

Exact text from the filing

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-23-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.